Overview

Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Status:
Not yet recruiting
Trial end date:
2030-01-11
Target enrollment:
Participant gender:
Summary
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
NRG Oncology
Collaborators:
Natera, Inc.
National Cancer Institute (NCI)